Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drug Safety
Published in: Drug Safety 12/2003

01-10-2003 | Correspondence

Nimesulide Controversy in India — Time to Learn

Authors: Arun K. Biswas, Krishan C. Singhal

Published in: Drug Safety | Issue 12/2003

Login to get access

Excerpt

It was very distressing to learn about liver toxicities associated with the use of nimesulide in India.[1] It is a matter of great concern that serious and fatal adverse drug reactions (ADRs) of drugs in India are unnoticed and do not result in appropriate regulatory action because of the inadequate regulatory systems in that country, and because of this situation the Indian pharmaceutical industry is still able to take full advantage of marketing medicines that are withdrawn in Western countries. …
Literature
1.
2.
Dhaon BK, Singh OP, Sharma S. Double-blind randomised comparative evaluation of efficacy and safety of nimulid (nimesulide) and diclofenac in osteoarthritis. Indian J Orthopaedics 1998 Apr; 32(2): 91–3
3.
Sharma VK, Srivastava R, Sharma S, et al. Comparative efficacy and safety of nimesulide vs piroxicam in osteoarthritis. Indian J Orthopaedics 1999 Jul; 33(3): 212–6
4.
Sharma S, Rastogi S, Gupta V, et al. Comparative efficacy and safety of nimesulide vs piroxicam in osteoarthritis with special reference to chondroprotection. Am J Ther 1999; 6: 191–7PubMedCrossRef
5.
Goyal PK, Chandra J, Unnikrishnan G, et al. Double blind randomised comparative evaluation of nimesulide and paracetamol as antipyretics. Indian Paediatr 1998 Jun; 35: 519–22
6.
Roy V, Gupta U, Sharma S, et al. Comparative efficacy and tolerability of nimesulide and piroxicam in osteoarthritis with specific reference to chondroprotection: a double blind randomised study. J Indian Med Assoc 1999; 97(10): 442–5PubMed
7.
Srishyla MV, Sireesha K, Bhaduri J, et al. A country wide post-marketing surveillance of nimesulide suspension. Indian Paediatr 2002; 39: 310–1
8.
Lakshmi PK, Gundu Rao DA, Gore SB. Doctors’ preference for the location of a drug information centre leads to a hospital-based clinical pharmacy initiative in India. J Pharm Pract Res 2002 Sep; 32(3): 240–1
9.
Metadata
Title
Nimesulide Controversy in India — Time to Learn
Authors
Arun K. Biswas
Krishan C. Singhal
Publication date
01-10-2003
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 12/2003
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200326120-00005

Other articles of this Issue 12/2003

Drug Safety 12/2003 Go to the issue

Leading Article

Benefit-Risk Analysis

Review Article

Safety and Tolerability Profiles of Intranasal Antihistamines and Intranasal Corticosteroids in the Treatment of Allergic Rhinitis

Leading Article

Pharmacovigilance of Herbal Medicines

Original Research Article

Adverse Effects of ACE Inhibitors in Patients with Chronic Heart Failure and/or Ventricular Dysfunction